Corey Davis
Stock Analyst at HC Wainwright & Co.
(2.94)
# 1,406
Out of 5,127 analysts
17
Total ratings
75%
Success rate
25.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $41.44 | +841.12% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.67 | +7,412.02% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $41.06 | -2.58% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $7.53 | +2,157.64% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $7.34 | +172.48% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $26.02 | +92.16% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $160.25 | -10.14% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $41.44
Upside: +841.12%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.67
Upside: +7,412.02%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $41.06
Upside: -2.58%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $7.53
Upside: +2,157.64%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $7.34
Upside: +172.48%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $26.02
Upside: +92.16%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $160.25
Upside: -10.14%